About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNANCT04922814

Comparison for the Effect of Neuromuscular Blocking Agents Versus Sedation Alone on Severe ARDS Patients Due to COVID-19

Many questions about management of COVID-19 are still not answered. So, we recruit this study aiming to evaluate improvement of oxygenation in COVID-19 patients with severe ARDS, to improve morbidity ...

Lead sponsor: Assiut University•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Start Free Trial

Sponsors

Lead Sponsor

Assiut University

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Severe ARDS: PaO2/FiO2 \<200, resistant hypoxemia and tachypnoea (RR \> 40 breath/minute)
•Not relieved by high frequency nasal canula or CPAP.
•Need for invasive mechanical ventilation (uncooperative)

Exclusion Criteria

•Patient relatives' refusal
•Not mechanically ventilated.
•Combination of female, corticosteroids administration and vecuronium muscle relaxant.
•Neuromuscular diseases (especially demyelinating diseases).

Related studies

Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine

NCT06402318 · COVID-19, SARS CoV 2 Virus, and more

Predictive Validity of the Chelsea Critical Care Physical Assessment Tool (CPAx) for Regaining Autonomy Three Months After ICU Discharge

NCT07167121 · ICU Acquired Weakness, Intensive Care Neuropathy

RECRUITINGPhase 3

Goal-Directed Sedation in Mechanically Ventilated Infants and Children

NCT04801589 · Delirium, Critical Illness, and more

Feasibility and Safety of Digital Rehab Platform for Bedridden Patients

NCT06849765 · ICU Acquired Weakness (ICUAW)

Validation of a Processed EEG Device for Monitoring Sedation in PICU

NCT05969483 · Sedation Complication

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 24, 2025Terms

Trial snapshot

StatusCOMPLETED

PhaseNA

Enrollment40

Start dateAug 2021

Last updatedDec 24, 2025

Condition

COVID-19 Acute Respiratory Distress Syndrome Sedation Complication ICU Acquired Weakness

Locations shown

Assiut university, faculty of medicine, anesthesia and ICU and pain management department

Asyut, Asyut Governorate

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 24, 2025Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions